Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug regulators in driving seat in planned ICH reforms

This article was originally published in Scrip

Executive Summary

Wide-ranging governance reforms are being considered at the International Conference on Harmonisation to redefine the respective roles of regulators and industry in developing harmonised guidelines for the pharmaceutical sector. Global expansion of the initiative is likely under the reform, with the possibility of Brazil, Russia, China, India and other countries progressively joining the US, the EU and Japan as members.

You may also be interested in...



How Saudi Arabia Differs From The EU On Pharmacovigilance Inspections

The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.

EMA To Beef Up Guidance On Additional Risk Minimization Tools

Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.

ICH Guide On Selective Reporting Of Safety Data Faces Major Rewrite

The International Council for Harmonisation is making big changes to its E19 guideline that proposes taking a targeted approach to safety data collection in some late-stage clinical trials. The draft guideline, which is largely similar to the US guideline on this topic, drew varied comments from stakeholders, including those from the EU. 

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel